US Patent 7662851 Use of specific cyklolignans
Patent 7662851 was granted and assigned to Axelar AB on February, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2023
Golden AI
Edits made to:
Article (+376 characters)
Article
Patent abstract
The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly. A preferred compound is picropodophyllin.
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07662851 Use of specific cyklolignans US Patent 7662851 Use of specific cyklolignans
Infobox
Patent Number
0766285100
Patent Number
766285100
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 30 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
0
Patent Jurisdiction
Patent Number
076628510
Date of Patent
February 16, 2010
0Patent Application Number
120215780
Date Filed
January 29, 2008
0Official Website
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
0
Patent Jurisdiction
Patent Number
076628510
Date of Patent
February 16, 2010
0Patent Application Number
120215780
Date Filed
January 29, 2008
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07662851 Use of specific cyklolignans
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07662851
Date of patent
February 16, 2010
Patent application number
12021578
Date Filed
January 29, 2008
Patent primary examiner
Find more entities like US Patent 7662851 Use of specific cyklolignans
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.